Gregory Frost, Ph.D.Chairman & CEO
Laurel MartinVP Finance and Controller
Monica Zepeda, Ph.D.VP Alliance and Global Operations
Tim Mayall, Ph.D.Head of Process Development
Farzad Haerizadeh, Ph.D.VP Platform Development
Greg Schreiber, Ph.D.Senior Director, IP and Licensing
Lazaro RodriguezSenior Director, IT and Connectivity
Alissa Kerner, Ph.D.Associate Director, New Product Planning
Scooter Willis, Ph.D.Senior Director, R&D Bioinformatics
Wendy Li, M.D. Chief Medical Officer, EXUMA Biotechnology
Chenghua MaGeneral Manager, Shenzhen, EXUMA Biotechnology
Lili Sui, Ph.D.General Manager, Shanghai, EXUMA Biotechnology
Hongliang Zong, Ph.D.VP Production, Research & Development, EXUMA Biotechnology
Dr. Frost has been Managing Director of F1 BioVentures, LLC since 2015. Previously, he led the Health Sector of Intrexon Corporation, a multinational public biotechnology company, where he was responsible for expanding their oncology franchise and gene and cellular-based therapies for a number of orphan diseases. From 1999 to 2014, Dr. Frost was at Halozyme Therapeutics, a San Diego public biotechnology company he co-founded, focused on oncology biologics and medication delivery, where he served on the Board of Directors and in numerous operational roles, including Chief Scientific Officer since 2002, and CEO since 2010. He has authored multiple scientific peer-reviewed and invited articles, and is an inventor on key patents supporting a number of FDA approved biologics. Dr. Frost is a member of the American Society of Clinical Oncology, the American Association for Cancer Research and is registered to practice before the U.S. Patent and Trademark Office. Dr. Frost earned his B.A. in biochemistry and molecular biology from the University of California, Santa Cruz, his Ph.D. in the Department of Pathology at the University of California, San Francisco and postdoctoral research at the Sidney Kimmel Cancer Center. As an entrepreneur, Dr. Frost brought the founding platform technologies to Halozyme and secured the initial capital for the company. In 2012, Gregory Frost was named by Forbes as one of Americas 20 most powerful CEO’s 40 and under, and was a finalist for Ernst and Young’s Entrepreneur of the Year in San Diego. Dr. Frost additionally serves on the Board of Directors of BioCom, a member-driven organization serving the life science community of Southern California and BioAtla, LLC.
Ms. Martin joined F1 Oncology in January 2017 as a Vice President, Finance and Controller and is responsible for the accounting and finance of the Company including the Cayman subsidiary and Asia operations. Prior to joining F1 Oncology, she served as Vice President, Finance and Corporate Controller of Halozyme Therapeutics, Inc., a San Diego publicly traded biotechnology company, from 2004 to 2016. She also served as Director of Finance of Ambit Biosciences from 2000 to 2003 and prior to that held various positions in the finance and accounting field. Ms. Martin began her career at Arthur Andersen where she obtained her CPA license. She earned her Bachelor of Business Administration in Accounting from the University of Texas at Austin.
Dr. Zepeda brings over 20 years of drug development experience in the biopharmaceutical arena, with a particular focus in entrepreneurial start-ups. Prior to joining F1 Oncology, she was an Alliance and Technical Lead for Halozyme Therapeutics including the Roche-Genentech alliance where she was instrumental in leading three US and EU drug approvals for world class biologics. Dr. Zepeda also held positions in leading preclinical candidacy teams for Canji/Schering Plough-Merck in novel gene therapy approaches for cancer and rare disease. Dr. Zepeda earned a B.A. in Physiology from the University of California, San Diego and a Ph.D. in Cellular and Molecular Engineering from the University of Michigan.
Dr. Timothy Mayall joined F1 Oncology in June 2016 as Head of Process Development, where he leads all process development activities for the genetic modification of adoptive cellular therapies, including analytical methods and technology transfer and scale-up into GMP operations. From 2008 to 2013, Dr. Mayall was Senior Director of Research and Development at PaxVax Inc. Joining the early PaxVax team as Senior Director of Molecular Biology and Virology, he was responsible for the development of their adenovirus, type 4 platform for the development of vaccines against pandemic flu, anthrax and HIV. He was involved in INDs for all three programs, as well as supporting efforts to reintroduce a cholera vaccine. At PaxVax, he worked on novel cell substrates for vaccine production, resulting in the presentation of A549 cells for vaccine manufacture at a VERPAC meeting and a master file to support INDs. From 2000 to 2005, Dr. Mayall was at Canji Inc., a former Schering-Plough subsidiary, in molecular biology focusing on transcriptional regulation of adenoviral and therapeutic genes including early work on molecular switches and methods for adenovirus library construction. As one of the core members of the San Diego team, he worked on the final replication-defective virus/production cell line system for the treatment of bladder cancer. Dr. Mayall came to San Diego for his postdoctoral studies at the Salk Institute for Biological Studies in La Jolla where he later became a staff scientist. Dr. Mayall earned his BSc. (Hons) in Biochemistry from the University of Leeds and his Ph.D. in molecular biology from the University of London, United Kingdom.
Dr. Haerizadeh joined F1 Oncology in 2016 where he is responsible for the development of global high throughput molecular screening technologies as well as the engineering of novel cell substrates. Dr. Haerizadeh joined F1 Oncology most recently from Synthetic Genomics Inc., where he was responsible for leads and platforms in the mammalian synthetic biology and xenotransplantation division. Previously, he was Director of genome editing and cell engineering division at Intrexon Corporation, where he focused on molecular and cellular engineering tools and platforms for health-related applications. Prior to Intrexon, Dr. Haerizadeh was a group leader in synthetic biology division at Life Technologies Corporation, a global leader in life science research tools, where he led various programs for mammalian synthetic biology and cell engineering related products and services including genome editing technologies. He was also involved in business development evaluation across the synthetic biology division. Prior to Life Technologies, Dr. Haerizadeh held key R&D roles at Codexis Inc., a leading protein engineering and enzyme evolution company. Dr. Haerizadeh received his PhD in molecular and systems biology from the University of Melbourne, Australia. He completed postdoctoral fellowships at Stanford University and the University of Melbourne.
Dr. Schreiber joined F1 Oncology as the Senior Director of IP Strategy & Licensing in April 2016. He brings more than 14 years of experience in intellectual property protection and patent portfolio development through licensing. Previously, Dr. Schreiber led the Office of Academic Alliances and Technology Licensing at Intrexon Corporation. From 2006-2015, he was a member of the corporate development and legal teams at Invitrogen, Life Technologies and Thermo Fisher Scientific, where he was responsible for in-licensing technologies that formed the basis of more than a dozen commercial product lines for cell and molecular biology research. Prior to entering industry, he was an Associate Director in the technology licensing office at The Johns Hopkins University. Dr. Schreiber is registered to practice before the U.S. Patent and Trademark Office and is a Certified Licensing Professional. He received his B.A. in biochemistry from the University of California, Berkeley and his Ph.D. in immunology from Washington University.
Lazaro Rodriguez joined F1 Oncology in January 2017, bringing over 20 years of industry experience in global IT, compliance and cloud technology to the company spanning multiple industries. At F1 Oncology, Mr. Rodriguez is responsible for the overall global IT strategy, architecture, infrastructure and managed services, from discovery biology through GMP operations. Prior to F1 Oncology, Mr. Rodriguez was Senior Director of IT at Kedrion Biopharma, a multinational biopharmaceutical blood plasma products company. From 1998 to 2014, Mr. Rodriguez worked at Maidenform, a $900M global retail business where he was most recently Senior Director of IT Infrastructure and Operations. Mr. Rodriguez has developed IT teams and data centers across the US, Europe, Asia and Central America with responsibility over global partnerships, change management, and technology leadership. Mr. Rodriguez studied Computer Science at Phoenix University.
Dr. Kerner serves as F1 Oncology’s Associate Director of New Product Planning and has been with the company since November 2016. She is currently responsible for market sizing, opportunity analysis, patient access, and medical communications for F1 Oncology’s programs in the US and Asia. Prior to F1 Oncology, she was an Engagement Manager for Boston Strategic Partners (BSP), a healthcare consulting firm in Boston, MA, where she managed projects in all three of the firm’s practices: Business Strategy, Health Economics and Outcomes Research, and Medical Communications. Dr. Kerner has extensive experience engaging and recruiting key opinion leaders and has worked on various types of projects including drug pricing and reimbursement strategy, market sizing, financial forecasting, competitive landscape assessments, publication planning, and strategic marketing. Dr. Kerner earned her B.S. degree in Chemical Engineering from the Massachusetts Institute of Technology and her M.S. and Ph.D. degrees in Biomedical Engineering from the University of Michigan. While at BSP, she participated in several mentoring and networking programs for women in STEM fields such as the Healthcare Businesswomen’s Association Mentoring Program and the GWAMIT (Graduate Women at MIT) Mentoring Program.
Dr. Willis joined F1 Oncology in 2018, where he is responsible for the company’s big data analytics programs as Senior Director of R&D Bioinformatics. From 2014 to 2018, Dr. Willis was Director of Computational Biology at the Avera Cancer Institute Center for Precision Oncology, responsible for the identification of prognostic and predictive genomic biomarkers in breast cancer clinical trials. While at Avera, he developed a genomic-centric EMR system to track a range of genomic tests used in supportive treatment plans for neo-adjuvant protocols. Dr. Willis is active in a range of emerging technologies focused on AI/Deep Learning to automate TIL calling to guide immunology treatment strategies in cancer. From 2012 to 2014, Dr. Willis was Director of Computational Bioinformatics at the Edith Sanford Breast Cancer Institute. From 2007 to 2012, Dr. Willis was a Data Analyst Scientist at Scripps Florida, where he developed software to automate the detection and identification of peptides in HDX Mass Spectrometry to interrogate protein structural dynamics to test the efficacy of drug candidates against target proteins. Dr. Willis earned his BSc in Electrical Engineering, Masters in Computer Science, MBA and Ph.D. in Computer Engineering from the University of Florida, where he also serves on the UFAA board of directors.
Wendy Li brings 10 years of clinical practice and over 20 years of hand-on experience in providing medical and scientific leadership in clinical research in oncology and other therapeutic areas, with previous experience in oncology clinical development at Genentech, Sanofi, and Pfizer. For the last two years, Dr. Li has been Medical Head and Vice President of Clinical Development for an EU Biotechnology start up where she provided medical and clinical guidance in the review and evaluation of immuno-oncology products. Prior to this position, she held a VP/CMO position with Sihuan Pharma/Co-Xuanzhu Pharma. She has provided leadership on global early and late stage clinical studies, responded to FDA/CFDA and related agencies, and advised clinical, marketing, regulatory, and pharmacovigilance teams. Dr. Li received her M.D. from the Sun Yat-Sen University of Medical Studies in China.
Mr. Ma has been the General Manager of Exuma Shenzhen since June 2018. Previously, he served as the CMC technical lead of two Adeno-associated virus (AAV)-based gene therapy clinical programs and managed gene therapy manufacturing technologies at Selecta Biosciences. From 2012 to 2016, Mr. Ma worked at Shire Pharmaceutical Inc. on commercial production of biological therapeutic products and at Voyager Therapeutics Inc. on AAV manufacturing technology development. From 2004 to 2012, Mr. Ma was at Genzyme Corporation (now Sanofi Pharmaceutical Inc.), focused on developing AAV-based gene therapy manufacturing technologies and clinical trial material generation. Mr. Ma earned his B.S. in virology and molecular biology from Wuhan University, Wuhan, China, his M.S. in microbiology from the Chinese Academy of Sciences, Beijing, China, and a M.S. in Biochemistry and Molecular Biology from the University of Maine, Maine, USA.
Dr. Sui has been the General Manager of Shanghai EXUMA Biotechnology since December 2018. Previously, she was the CEO of Shanghai PerHum Therapeutics from December 2017 to November 2018 where she was responsible for the business transformation from research to pharmaceutical development and led the R&D, POC clinical trial and IND registration for the company’s first two CAR-T products. From 2015-2017, she was the GM of Shanghai Yitai Biotechnology where she led the merger and acquisition of Yitai with Dongcheng Pharmaceuticals, and was involved in multiple other acquisition activities, as well as initiating the introduction of a US product to the Chinese market. Dr. Sui received her B.S. and M.S. degrees in the Inner Mongolia Medical College, Ph.D. from the First Military Medical University, and was trained as a postdoc in immunology in the Second Military Medical University.
Dr. Zong has been the Vice President of Production, Research & Development for EXUMA Biotech since December 2018. He was previously the Vice President of Production, Research & Development for PerHum Therapeutics from June 2017 to November 2018 where he was responsible for CAR-T manufacturing related production, warehouse management, purchasing, cell process R&D, CRO collaboration and clinical trial-related molecular diagnostic technologies. He was the Chief Scientific Officer of Tofflon Healthcare from April 2016 to June 2017, where he led the R&D team to development and preclinical studies for the universal CAR-T product targeting hematologic malignancies and solid tumors. Dr. Zong earned his B.M. in Preventative Medicine and Ph.D. in Biochemistry and Molecular Biology from Shanghai Medical College of Fudan University.
Board of Directors
Jay Short, Ph.D.
Dr. Short is Chairman, CEO, President and co-founder of BioAtla, headquartered in San Diego with operations in Beijing, pioneering Conditionally Active Biologic (CAB) cancer therapies. He is Chairman and co-founder of LusBio for waste biomass conversion to feed and food production. He was founder and President of the E.O. Wilson Biodiversity Foundation and, prior to this, was co-founder of Diversa (now BASF), a pioneer in protein discovery and evolution from microbial biodiversity, where he served as CEO, President and CTO and led the company in achieving the largest biotech IPO. Dr. Short also served as President of Stratacyte, an antibody engineering company, and VP of Research & Development and Operations for Stratagene (now Agilent), a leading research supply company. He earned his PhD in Biochemistry at CWRU and his BA in chemistry with honors at Taylor University.
Dr. Short received San Diego’s 2001 E&Y Entrepreneur of the Year Award and was the recipient of two first place awards from UCSD- Connect Innovative Product Program. He has authored more than 100 publications and is named inventor of over 300 issued patents and several hundred pending patents, which in 2011 led to the MDB Capitals’ CLARUS Award for disruptive and market changing intellectual property. His patents ranked in the top ten based on citation frequency on the 2003 and 2004 Patent Scorecard by MIT Survey across all industries. In addition, Dr. Short’s grant programs were in the top one percent of SBIR research programs. He has served on the NRC panel for Chemical Science and Technology at NIST. In 2003 he received the ABL Innovations in HealthCare Gold award, and in 2004 he received the Henry F. Whalen, Jr. Award for Business Development by ACS. In 2006 Dr. Short was shortlisted by the editors of Nature Biotechnology as a personality making the most significant contribution to biotech in the past decade. In 2010 he received an International Best-of-the-Best award from YPO. Dr. Short also serves as an advisor to multiple educational, commercial, scientific and charitable organizations.
David A. Ramsay
Mr. Ramsay retired from Halozyme Therapeutics, Inc. (NASDAQ: HALO) in July 2015, where he served as Chief Financial Officer since May 2013 and from 2003 to May 2009. He also served as Halozyme’s Vice President, Corporate Development from May 2009 to May 2013. From 2000 to 2003, Mr. Ramsay was Vice President, Chief Financial Officer of Lathian Systems, Inc., a provider of technology-based sales solutions for the life science industry. From 1998 to 2000, he was with Valeant Pharmaceuticals International, Inc. (formerly ICN Pharmaceuticals, Inc.), where he served as Vice President, Treasurer and Director, Corporate Finance. Mr. Ramsay began his career at Deloitte & Touche, where he obtained his CPA license. Mr. Ramsay also sits on the boards of Savara, Inc., and Bonti. He holds a B.S. in business administration from the University of California, Berkeley and an M.B.A. with a dual major in finance and strategic management from The Wharton School at the University of Pennsylvania.